Clindamycin Phosphate Injection

1. This product is a chemically semi-synthetic clindamycin derivative. It has no antibacterial activity in vitro. After entering the body, it is rapidly hydrolyzed into clindamycin and shows its pharmacological activity. Therefore, the antibacterial spectrum, antibacterial activity and therapeutic effect are the same as those of clindamycin, but its fat solubility and permeability are better than those of clindamycin, and it can be administered by intramuscular injection and intravenous drip. 2. Compared with lincomycin, this product has a 4-8 times stronger antibacterial effect, good absorption, high bone concentration, and good efficacy against anaerobic infections. 3. This product has strong antibacterial activity mainly against Gram-positive cocci and anaerobic bacteria, including Gram-positive cocci: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (except Streptococcus phosphotrophicus), Streptococcus pneumoniae, Micrococcus, etc.; anaerobic bacteria: Clostridium, Bacteroides, Clostridium, Propionibacterium, Eubacterium, anaerobic cocci, etc.

Clindamycin phosphate.

Used for the following infectious diseases caused by Gram-positive bacteria: 1. Tonsillitis, suppurative otitis media, sinusitis, etc. 2. Acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, lung abscess and bronchiectasis combined infection, etc. 3. Skin and soft tissue infections: furuncle, carbuncle, abscess, cellulitis, trauma, burns and postoperative infection, etc. 4. Urinary tract infections: acute urethritis, acute pyelonephritis, prostatitis, etc. 5. Others: osteomyelitis, sepsis, peritonitis and oral infection, etc. Used for various infectious diseases caused by anaerobic bacteria: 1. Empyema, lung abscess, anaerobic pneumonia. 2. Skin and soft tissue infections, sepsis. 3. Intra-abdominal infections: peritonitis, intra-abdominal abscess. 4. Female pelvic and genital infections: endometritis, non-gonococcal fallopian tuberculosis

This product can be administered by deep intramuscular injection or intravenous drip. When intravenously dripping, every 0.3g needs to be diluted with 50-100ml of normal saline or 5% glucose solution to a concentration of less than 6mg/ml, and drip slowly, usually not more than 20mg per minute. 1. Mild to moderate infection: Adults: 0.6-1.2g per day, divided into 2-4 doses (q12h-q6h), children: 15-25mg/kg per day according to body weight, divided into 2-4 doses (q12h-q6h). 2. Severe infection: Adults: 1.2-2.7g per day, divided into 2-4 doses (q12h-q6h), children: 25-40mg/kg per day according to body weight, divided into 2-4 doses (q12h-q6h).

1. After intramuscular injection, slight pain may occasionally occur at the injection site. Long-term intravenous infusion may cause phlebitis. 2. Gastrointestinal reactions: nausea, vomiting, abdominal pain and diarrhea may occur occasionally. 3. Allergic reactions: a few patients may develop drug-induced rash. 4. Occasionally, it may cause neutropenia or eosinophilia. 5. A few patients may experience transient alkaline phosphatase, mild elevation of serum chlorotransferase and jaundice. 6. A very small number of patients may develop pseudomembranous colitis.

This product has cross-resistance with lincomycin and clindamycin and is contraindicated in patients with a history of allergy to clindamycin or lincomycin.

Precautions for children: Use with caution in children under 4 years old. Precautions for pregnancy and lactation: No studies have been conducted on pregnant women, but no effects on the fetus have been seen in animal reproduction studies, and the therapeutic benefits of using this drug for pregnant women may outweigh its potential harms. Alternatively, this drug has not been tested on animals, and there have been no sufficiently rigorous controlled studies on pregnant women. Pregnant and lactating women should be careful when using this product. Precautions for the elderly:

This product is antagonistic to erythromycin and should not be used together.

Keep in a sealed container and away from light.

4ml:0.6g (calculated as C18H33ClN2O5S)

Two years

Shandong Xinhua Pharmaceutical Company Limited

• Founded in:

  1998-11-20

• Address:

  Chemical Industry Zone, Zibo High-tech Industrial Development Zone

• Tax NO.:

  91370300164103727C

• Registered Funds:

  682,407,635 yuan

• Website:

  Log in to view

• Email:

  Log in to view